You just read:

Novartis Pharmaceuticals Canada Inc. receives a Notice of Compliance from Health Canada for Seebri™ Breezhaler* as a long-term once-daily maintenance COPD treatment in Canada

News provided by

Novartis Pharmaceuticals Canada Inc.

Oct 22, 2012, 08:00 ET